SGMT Profile
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative therapeutics targeting fatty acid synthase (FASN) to address diseases linked to dysfunctional lipid metabolism pathways. The company's primary focus is on creating FASN inhibitors that can potentially transform the treatment landscape for various conditions related to lipid metabolism. Its lead candidate, Denifanstat, is a FASN inhibitor currently in development for the treatment of nonalcoholic steatohepatitis (NASH) and acne, aiming to offer new therapeutic options for these challenging conditions.
In addition to Denifanstat, Sagimet Biosciences is advancing its research with TVB-3567, another FASN inhibitor being developed to address multiple types of cancers. The company's approach leverages its expertise in lipid metabolism to explore novel treatments for cancer and other diseases where abnormal lipid synthesis plays a significant role. This broad therapeutic pipeline highlights Sagimet's commitment to addressing unmet medical needs across a range of complex and challenging health conditions.
Originally incorporated as 3-V Biosciences, Inc. in 2006, the company rebranded as Sagimet Biosciences Inc. in August 2019 to better reflect its focus on metabolic disorders and lipid-related diseases. Headquartered in San Mateo, California, Sagimet Biosciences operates at the cutting edge of biopharmaceutical research, employing advanced scientific methodologies and clinical trials to develop and refine its therapeutic candidates.
With a strategic focus on lipid metabolism and its associated diseases, Sagimet Biosciences is positioned to make significant contributions to the treatment of metabolic and oncology-related conditions. The company's ongoing research and development efforts underscore its dedication to pioneering new solutions and advancing the field of biopharmaceuticals with innovative, targeted therapies.
|
